Lyn Rees, Proactive London Interview 2019
Yourgene Health PLC (LON:NIPT) chief executive Lyn Rees tells Proactive London's Andrew Scott they've been making excellent commercial progress with their flagship NIPT product.
In 2018 the firm entered into a legal settlement and licence agreement with Illumina, ending all patent litigation around the test.
"It feels as if we've pressed the reset button ... we knew we had this great technology, we knew the pregnant mums really loved this technology because it's faster and more effective, but because of the litigation it made it difficult to sell", Rees says.
"Now, we've got no litigation worries so we've got the whole world to look at from an addressable market perspective and the fact we're already in 20 countries, that gives us a good springboard to go into probably another 30 countries over the next three years".
Yourgene Health PLC (LON:NIPT) chief executive Lyn Rees tells Proactive London's Andrew Scott they've been making excellent commercial progress with their flagship NIPT product.
In 2018 the firm entered into a legal settlement and licence agreement with Illumina, ending all patent litigation around the test.
"It feels as if we've pressed the reset button ... we knew we had this great technology, we knew the pregnant mums really loved this technology because it's faster and more effective, but because of the litigation it made it difficult to sell", Rees says.
"Now, we've got no litigation worries so we've got the whole world to look at from an addressable market perspective and the fact we're already in 20 countries, that gives us a good springboard to go into probably another 30 countries over the next three years".
